新闻源 财富源

2019年10月22日 星期二

康缘药业(600557)公告正文

江苏康缘药业股份有限公司2006年第三季度报告

公告日期:2006-10-20


               江苏康缘药业股份有限公司2006年第三季度报告
     
    目录
   §1重要提示 3
    §2 公司基本情况 3
    §3 管理层讨论与分析 5
    §4 附录 8
     §1 重要提示
    
    1.1 本公司董事会及其董事保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 
     1.2 公司以通讯方式表决了本报告,全体董事参与了表决。 
     1.3 公司第三季度财务报告未经审计。 
    
    1.4 公司负责人肖伟,主管会计工作负责人戴翔翎,会计机构负责人(会计主管人员)陈友龙声明:保证本季度报告中财务报告的真实、完整。
    
    §2 公司基本情况
    
    2.1 公司基本信息
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  股票简称                康缘药业                                                                                     
  股票代码                600557                                                                                       
                          董事会秘书                                     证券事务代表                                  
  姓名                    程凡                                           宗韬                                          
  联系地址                连云港市新浦海昌南路58号                       连云港市新浦海昌南路58号                      
  电话                    0518-5521990                                   0518-5521990                                  
  传真                    0518-5521990                                   0518-5521990                                  
  电子信箱                chf@kanion.com                                 ztao731@kanion.com                            
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

    2.2 财务资料
    
    2.2.1 主要会计数据及财务指标
    币种:人民币
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
                                                 本报告期末            上年度期末             报告期末比上年度期末增减 
                                                                                              (%)                   
  总资产(元)                                     966,954,721.26        990,506,396.82         -2.38                    
  股东权益(不含少数股东权益)(元)               466,066,267.31        443,639,464.89         5.06                     
  每股净资产(元)                                 2.99                  2.84                   5.06                     
  调整后的每股净资产(元)                         2.96                  2.79                   6.09                     
                                                 报告期                年初至报告期期末       报告期比上年同期增减(% 
                                                                                              )                       
  经营活动产生的现金流量净额(元)                 -                     39,137,303.89          -                        
  每股收益(元)                                   0.11                  0.29                   38.92                    
  净资产收益率(%)                                3.84                  9.88                   增加0.71个百分点         
  扣除非经常性损益后的净资产收益率(%)            3.82                  9.75                   增加0.86个百分点         
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

     非经常性损益项目                                                          (单位:元)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  项目                                                                             金额                                
  减项:                                                                                                               
  处置长期股权投资收益                                                             269,554.84                          
  技术改造项目财政贴息及各项补贴                                                   604,000.00                          
  营业外收入                                                                       19,312.79                           
  债务重组收益                                                                     179,991.48                          
  所得税影响                                                                       354,043.51                          
  小计                                                                             718,815.60                          
  增项:                                                                                                               
  营业外支出                                                                       165,503.73                          
  所得税影响                                                                       54,616.23                           
  小计                                                                             110,887.50                          
  合计                                                                             607,928.10                          
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

    2.2.2 利润表
    单位: 元 币种:人民币 审计类型:未经审计 


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  项目                                      合并                                  母公司                               
                                            本期数 (7-9月)     上年同期数 (7-9   本期数 (7-9月)    上年同期数 (7-9  
                                                               月)                                   月)               
  一、主营业务收入                          203,070,339.49     206,892,876.02     130,770,188.76     123,049,224.48    
  减:主营业务成本                          85,017,644.66      88,714,915.60      33,406,225.62      26,196,813.09     
  主营业务税金及附加                        2,453,068.20       2,268,365.14       2,078,423.56       1,917,846.11      
  二、主营业务利润                          115,599,626.63     115,909,595.28     95,285,539.58      94,934,565.28     
  加:其他业务利润                          1,001,044.45       -180,109.46        471,420.48         -631,902.58       
  减:营业费用                               63,725,465.57      67,443,550.59      49,595,201.98      53,254,831.84     
  管理费用                                  24,389,337.23      26,421,151.09      19,581,991.62      21,248,813.04     
  财务费用                                  4,494,281.70       4,702,596.41       3,915,764.21       4,027,568.16      
  三、营业利润                              23,991,586.58      17,162,187.73      22,664,002.25      15,771,449.66     
  加:投资收益                              -36,266.18         337,178.68         371,449.36         1,091,883.46      
  补贴收入                                  -49,279.43                                                                 
  营业外收入                                11,855.98          126,152.18                            3,483.83          
  减:营业外支出                            79,979.04          470,461.24         20,936.50          412,220.00        
  四、利润总额                              23,837,917.91      17,155,057.35      23,014,515.11      16,454,596.95     
  减:所得税                                5,884,701.97       3,912,316.87       5,115,562.30       3,570,016.99      
  减:少数股东损益                          54,263.13          359,260.52                                              
  加:未确认投资损失                                                                                                   
  五、净利润                                17,898,952.81      12,884,579.96      17,898,952.81      12,884,579.96     
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

    
    
    2.3 报告期末股东总数及前十名无限售条件流通股股东持股表(已完成股权分置改革)
    单位:股


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  报告期末股东总数(户)                                             9,017                                             
  前十名无限售条件流通股股东持股情况                                                                                   
  股东名称(全称)                                                     期末持有无限售条件流通股   种类                   
                                                                     的数量                                            
  兴和证券投资基金                                                   7,303,049                  人民币普通股           
  交通银行-汉兴证券投资基金                                         3,668,300                  人民币普通股           
  全国社保基金一零四组合                                             3,666,327                  人民币普通股           
  汉盛证券投资基金                                                   3,647,542                  人民币普通股           
  中国工商银行-易方达价值精选股票型证券投资基金                     2,493,911                  人民币普通股           
  中国工商银行-建信优选成长股票型证券投资基金                       1,919,999                  人民币普通股           
  中国工商银行-诺安平衡证券投资基金                                 1,836,415                  人民币普通股           
  中国工商银行-银河银泰理财分红证券投资基金                         1,435,910                  人民币普通股           
  国际金融-中行-中金股票精选集合资产管理计划                       1,427,800                  人民币普通股           
  交通银行-普惠证券投资基金                                         1,225,095                  人民币普通股           
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

    §3 管理层讨论与分析
    
    3.1 公司报告期内经营活动总体状况的简要分析
    
    报告期,公司继续推进医院临床精细化管理,强化临床学术推广,克服医药市场环境变化带来的不利影响,立足现有产品结构挖掘潜力市场,使公司的主营业务继续保持稳定增长态势。年初至报告期末,公司实现主营业务收入638,399,515.33元,同比增长15.01%,实现净利润46,026,740.18元,同比增长42.11%,其中母公司实现主营业务收入390,321,997.74元,同比增长16.65%,实现净利润46,026,740.18元,同比增长42.11%。报告期,腰痹通胶囊、散结镇痛胶囊品种保持良好的增长势头,销售收入较上年同期分别增长了46.25%、116.48%;热毒宁注射液第三季度销售收入开始出现较大幅度的增长,前三季度累计实现销售收入824.11万元,其中第三季度实现销售收入372万元。
    报告期公司持续推进桂枝茯苓胶囊国际化认证工作,9月30日已向FDA正式递交临床申报资料。根据美国FDA的政策法规,自递交申报资料之日起,一个月内FDA没有提出异议,则公司可以正式在美国开展Ⅱ临床验证工作。
    
    
     3.1.1 占主营收入或主营业务利润总额10%以上的主营行业或产品情况
    √适用  □不适用
    单位:元 币种:人民币 审计类型:未经审计


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  分行业                       主营业务收入                       主营业务成本                     毛利率(%)           
  医药工业                     390,321,997.74                     98,386,483.69                    74.79               
  医药商业                     286,819,605.25                     218,318,355.96                   23.88               
  技术服务                     2,073,000.00                                                                           
  出口贸易                     13,957,168.25                      12,823,270.70                    8.12                
  其中:关联交易               54,772,255.91                      54,772,255.91                                        
  合计                         638,399,515.33                     274,755,854.44                   56.96               
  分产品                       主营业务收入                       主营业务成本                     毛利率(%)           
  胶囊                         343,659,159.10                     76,017,577.48                    77.88               
  口服液                       25,490,046.07                      9,666,546.71                     62.08               
  冲剂                         4,691,432.15                       3,945,971.06                     15.89               
  片、丸剂                     8,063,516.07                       6,120,813.35                     24.09               
  注射剂                       8,417,844.35                       2,635,575.09                     68.69               
  合计                         390,321,997.74                     98,386,483.69                    74.79               
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

    3.1.2 公司经营的季节性或周期性特征
    □适用  √不适用 
    
    3.1.3 报告期利润构成情况(主营业务利润、其他业务利润、期间费用、投资收益、补贴收入与营业外收支净额在利润总额中所占比例与前一报告期相比的重大变动及原因的说明)
    □适用  √不适用 
    
    3.1.4 主营业务及其结构与前一报告期相比发生重大变化的情况及原因说明
    □适用  √不适用 
    
    3.1.5 主营业务盈利能力(毛利率)与前一报告期相比发生重大变化的情况及其原因说明
    □适用  √不适用 
    
    3.2 重大事项及其影响和解决方案的分析说明
    √适用  □不适用 
        报告期内,本公司控股子公司连云港康缘医药商业有限公司将其持有的宿迁康缘商业医药有限公司51.14%的股权转让给了自然人陈通,并已于2006年8月11日完成工商变更手续。
    
    3.3 会计政策、会计估计、合并范围变化以及重大会计差错的情况及原因说明
    □适用  √不适用 
    
     3.4 经审计且被出具"非标意见"情况下董事会和监事会出具的相关说明
    □适用  √不适用 
    
    3.5 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动的警示及说明
    □适用  √不适用 
    
    3.6 公司对已披露的年度经营计划或预算的滚动调整情况
    □适用  √不适用 
    
    3.7 公司原非流通股东在股权分置改革过程中做出的特殊承诺及其履行情况
    √适用  □不适用


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  股东名称       特殊承诺                                                                           承诺履行情况       
  连云港康缘集   自所持公司非限售流通股份获得上市流通权之日起,在36个月内不上市交易或者转让;在上   遵照执行,未发生转 
  团有限公司     述期限届满之日起的24个月内,只有当公司股票价格连续10个交易日的收盘价格高于每股10   让我公司股份的行为 
                 元后,方可通过证券交易所挂牌交易出售原所持非流通股份(如遇公司分红、送股、转增股   。                 
                 本、配股、增发等导致股价除息或除权的,上述收盘价格进行相应调整)。                                    
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

    3.8 截止本次季报公告日,未进入股改程序公司的股改工作时间安排说明
    □适用  √不适用 
     截止本次季报公告日,未进入股改程序公司的相关说明
    □适用  √不适用 
    
     江苏康缘药业股份有限公司
    
    法定代表人:肖伟
    
    二〇〇六年十月十八日
     §4 附录
    资产负债表(一) 2006年09月30日
    编制单位: 江苏康缘药业股份有限公司               单位: 元 币种:人民币 审计类型:未经审计


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  项目                                   合并                                    母公司                                
                                         期末数              期初数              期末数             期初数             
  流动资产:                                                                                                           
  货币资金                               131,417,370.94      157,574,849.75      97,159,405.08      121,757,840.65     
  短期投资                                                                                                             
  应收票据                               29,719,714.74       30,672,540.81       24,957,517.08      27,751,752.04      
  应收股利                                                                                                             
  应收利息                                                                                                             
  应收账款                               240,907,229.42      193,650,398.11      164,982,601.53     120,658,470.58     
  其他应收款                             52,966,895.42       61,345,407.79       42,032,196.74      54,435,783.36      
  预付账款                               1,251,060.17        1,742,067.38                                              
  应收补贴款                             262,968.19          59,071.62                                                 
  存货                                   40,221,037.22       52,612,072.48       23,192,991.63      25,617,055.80      
  待摊费用                               369,510.30          269,823.93          133,500.00         111,000.00         
  一年内到期的长期债权投资                                                                                             
  其他流动资产                                                                                                         
  流动资产合计                           497,115,786.40      497,926,231.87      352,458,212.06     350,331,902.43     
  长期投资:                                                                                                           
  长期股权投资                           27,994,094.67       25,541,313.66       71,205,252.95      65,316,585.15      
  长期债权投资                                                                                                         
  长期投资合计                           27,994,094.67       25,541,313.66       71,205,252.95      65,316,585.15      
  其中:合并价差                                                                                                       
  其中:股权投资差额                                                                                                   
  固定资产:                                                                                                           
  固定资产原价                           386,545,367.59      389,639,904.04      369,788,526.67     366,736,597.50     
  减:累计折旧                           74,675,524.02       61,262,794.46       69,632,452.37      54,462,850.19      
  固定资产净值                           311,869,843.57      328,377,109.58      300,156,074.30     312,273,747.31     
  减:固定资产减值准备                   1,192,563.40        1,211,313.40        1,169,003.90       1,187,753.90       
  固定资产净额                           310,677,280.17      327,165,796.18      298,987,070.40     311,085,993.41     
  工程物资                                                                                                             
  在建工程                               57,253,198.34       43,659,539.91       49,483,198.34      35,889,539.91      
  固定资产清理                                                                                                         
  固定资产合计                           367,930,478.51      370,825,336.09      348,470,268.74     346,975,533.32     
  无形资产及其他资产:                                                                                                 
  无形资产                               71,929,047.65       92,946,847.44       43,686,535.75      52,717,322.77      
  长期待摊费用                           1,985,314.03        3,266,667.76        1,117,098.03       2,031,086.82       
  其他长期资产                                                                                                         
  无形资产及其他资产合计                 73,914,361.68       96,213,515.20       44,803,633.78      54,748,409.59      
  递延税项:                                                                                                           
  递延税款借项                                                                                                         
  资产总计                               966,954,721.26      990,506,396.82      816,937,367.53     817,372,430.49     
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

    公司法定代表人:肖伟          主管会计工作负责人: 戴翔翎         会计机构负责人: 陈友龙
     资产负债表(二)
    2006年09月30日
    编制单位: 江苏康缘药业股份有限公司               单位: 元 币种:人民币 审计类型:未经审计


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  项目                                   合并                                    母公司                                
                                         期末数              期初数              期末数             期初数             
  流动负债:                                                                                                           
  短期借款                               191,000,000.00      201,330,000.00      170,000,000.00     175,000,000.00     
  应付票据                               12,204,994.85       22,081,967.10       10,000,000.00      21,540,168.90      
  应付账款                               110,515,175.13      119,369,264.10      37,556,541.05      39,310,200.55      
  预收账款                               1,715,882.87        940,538.17                                                
  应付工资                               930,827.41          876,666.13                                                
  应付福利费                             3,430,071.41        3,880,849.74        1,860,680.50       1,975,122.09       
  应付股利                               1,868,053.60                            1,868,053.60                          
  应交税金                               17,650,414.90       19,456,914.52       14,138,281.18      14,593,140.48      
  其他应交款                             2,474,476.86        2,616,236.08        2,463,035.54       2,505,200.49       
  其他应付款                             51,510,767.42       58,934,851.25       36,060,389.25      35,729,062.55      
  预提费用                               2,579,808.10        1,354,547.16        1,958,684.83       1,182,664.00       
  预计负债                                                                                                             
  一年内到期的长期负债                   33,312,452.49       33,162,452.49       13,750,000.00      13,600,000.00      
  其他流动负债                                                                                                         
  流动负债合计                           429,192,925.04      464,004,286.74      289,655,665.95     305,435,559.06     
  长期负债:                                                                                                           
  长期借款                               48,450,000.00       58,800,000.00       48,450,000.00      58,800,000.00      
  应付债券                                                                                                             
  长期应付款                                                                                                           
  专项应付款                             13,330,900.00       9,810,900.00        13,330,900.00      9,810,900.00       
  其他长期负债                                                                                                         
  长期负债合计                           61,780,900.00       68,610,900.00       61,780,900.00      68,610,900.00      
  递延税项:                                                                                                           
  递延税款贷项                                                                                                         
  负债合计                               490,973,825.04      532,615,186.74      351,436,565.95     374,046,459.06     
  少数股东权益                           9,914,628.91        14,251,745.19                                             
  所有者权益(或股东权益):                                                                                           
  实收资本(或股本)                     156,060,000.00      156,060,000.00      156,060,000.00     156,060,000.00     
  减:已归还投资                                                                                                       
  实收资本(或股本)净额                 156,060,000.00      156,060,000.00      156,060,000.00     156,060,000.00     
  资本公积                               168,159,729.56      166,790,067.32      167,594,263.83     166,476,573.86     
  盈余公积                               34,623,079.52       34,623,079.52       34,623,079.52      34,623,079.52      
  其中:法定公益金                                           1,966,439.72                           1,966,439.72       
  未分配利润                             107,223,458.23      86,166,318.05       107,223,458.23     86,166,318.05      
  拟分配现金股利                                                                                                       
  外币报表折算差额                                                                                                     
  减:未确认投资损失                                                                                                   
  所有者权益合计                         466,066,267.31      443,639,464.89      465,500,801.58     443,325,971.43     
  负债和所有者权益总计                   966,954,721.26      990,506,396.82      816,937,367.53     817,372,430.49     
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
公司法定代表人:肖伟          主管会计工作负责人: 戴翔翎         会计机构负责人: 陈友龙
     利润表
    2006年09月30日
    
    编制单位: 江苏康缘药业股份有限公司               单位: 元 币种:人民币 审计类型:未经审计


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  项目                                      合并                                  母公司                               
                                            本期数 (1-9月)     上年同期数 (1-9月  本期数 (1-9月)     上年同期数 (1-9月 
                                                               )                                     )                 
  一、主营业务收入                          638,399,515.33     555,076,114.87     390,321,997.74     334,623,669.03    
  减:主营业务成本                          274,755,854.44     242,029,642.88     98,386,483.69      77,101,664.04     
  主营业务税金及附加                        7,616,026.46       6,348,128.96       6,314,849.66       5,315,249.05      
  二、主营业务利润                          356,027,634.43     306,698,343.03     285,620,664.39     252,206,755.94    
  加:其他业务利润                          2,985,565.46       1,299,325.27       974,898.83         -249,642.65       
  减:营业费用                               204,200,630.40     180,446,271.87     155,897,547.54     145,355,895.53    
  管理费用                                  75,968,267.61      69,197,768.71      60,144,026.63      53,961,922.56     
  财务费用                                  12,667,276.45      11,792,566.83      10,630,559.31      10,606,050.05     
  三、营业利润                              66,177,025.43      46,561,060.89      59,923,429.74      42,033,245.15     
  加:投资收益                              397,714.85         674,140.46         3,373,836.31       2,981,911.09      
  补贴收入                                                     47,841.09                                               
  营业外收入                                19,312.79          234,862.84         556.81             103,412.05        
  减:营业外支出                            182,064.68         647,653.08         36,387.50          484,382.00        
  四、利润总额                              66,411,988.39      46,870,252.20      63,261,435.36      44,634,186.29     
  减:所得税                                19,666,320.43      13,650,766.49      17,234,695.18      12,245,572.35     
  减:少数股东损益                          718,927.78         831,971.77                                              
  加:未确认投资损失                                                                                                   
  五、净利润                                46,026,740.18      32,388,613.94      46,026,740.18      32,388,613.94     
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

    公司法定代表人:肖伟          主管会计工作负责人: 戴翔翎         会计机构负责人: 陈友龙
    
    
     现金流量表(一) 2006年09月30日
    
    编制单位: 江苏康缘药业股份有限公司               单位: 元 币种:人民币 审计类型:未经审计


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  项目                                                       合并数                        母公司数                    
  一、经营活动产生的现金流量:                                                                                         
  销售商品、提供劳务收到的现金                               642,828,568.77                358,891,688.32              
  收到的税费返还                                             875,876.92                                                
  收到的其他与经营活动有关的现金                             1,853,446.62                  774,698.48                  
  现金流入小计                                               645,557,892.31                359,666,386.80              
  购买商品、接受劳务支付的现金                               262,959,116.51                50,621,973.09               
  支付给职工以及为职工支付的现金                             62,923,907.40                 39,787,180.94               
  支付的各项税费                                             98,752,621.28                 82,352,263.09               
  支付的其他与经营活动有关的现金                             181,784,943.23                147,640,484.40              
  现金流出小计                                               606,420,588.42                320,401,901.52              
  经营活动产生的现金流量净额                                 39,137,303.89                 39,264,485.28               
  二、投资活动产生的现金流量:                                                                                         
  收回投资所收到的现金                                       5,604,980.00                  604,980.00                  
  其中:出售子公司收到的现金                                 5,604,980.00                  604,980.00                  
  取得投资收益所收到的现金                                   90,000.00                                                 
  处置固定资产、无形资产和其他长期资产而收回的现金           1,628,662.90                  681,564.38                  
  收到的其他与投资活动有关的现金                                                                                       
  现金流入小计                                               7,323,642.90                  1,286,544.38                
  购建固定资产、无形资产和其他长期资产所支付的现金           20,917,027.65                 19,853,249.16               
  投资所支付的现金                                           2,424,621.00                  2,182,113.00                
  支付的其他与投资活动有关的现金                             3,941,219.36                                              
  现金流出小计                                               27,282,868.01                 22,035,362.16               
  投资活动产生的现金流量净额                                 -19,959,225.11                -20,748,817.78              
  三、筹资活动产生的现金流量:                                                                                         
  吸收投资所收到的现金                                                                                                 
  其中:子公司吸收少数股东权益性投资收到的现金                                                                         
  借款所收到的现金                                           149,330,000.00                145,000,000.00              
  收到的其他与筹资活动有关的现金                             4,124,000.00                  4,124,000.00                
  现金流入小计                                               153,454,000.00                149,124,000.00              
  偿还债务所支付的现金                                       164,530,000.00                160,200,000.00              
  分配股利、利润或偿付利息所支付的现金                       34,259,557.59                 32,038,103.07               
  其中:支付少数股东的股利                                                                                             
  支付的其他与筹资活动有关的现金                                                                                       
  其中:子公司依法减资支付给少数股东的现金                                                                             
  现金流出小计                                               198,789,557.59                192,238,103.07              
  筹资活动产生的现金流量净额                                 -45,335,557.59                -43,114,103.07              
  四、汇率变动对现金的影响                                                                                             
  五、现金及现金等价物净增加额                               -26,157,478.81                -24,598,435.57              
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

    公司法定代表人:肖伟         主管会计工作负责人: 戴翔翎           会计机构负责人: 陈友龙
     现金流量表(二) 2006年09月30日
    
    编制单位: 江苏康缘药业股份有限公司               单位: 元 币种:人民币 审计类型:未经审计


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  项目                                                       合并数                        母公司数                    
  补充材料                                                                                                             
  1、将净利润调节为经营活动现金流量:                                                                                  
  净利润                                                     46,026,740.18                 46,026,740.18               
  加:少数股东损益(亏损以“-”号填列)                        718,927.78                                                
  减:未确认的投资损失                                                                                                 
  加:计提的资产减值准备                                     1,389,023.24                  929,151.08                  
  固定资产折旧                                               16,751,605.48                 15,709,525.59               
  无形资产摊销                                               9,712,931.36                  9,030,787.02                
  长期待摊费用摊销                                           1,142,889.01                  913,988.79                  
  待摊费用减少(减:增加)                                   -905.26                       -22,500.00                  
  预提费用增加(减:减少)                                   -133,042.81                   -575,200.00                 
  处理固定资产、无形资产和其他长期资产的损失(减:收益)        -5,272.79                     -556.81                     
  固定资产报废损失                                                                                                     
  财务费用                                                   12,610,749.14                 10,630,559.31               
  投资损失(减:收益)                                       -397,714.85                   -3,373,836.31               
  递延税款贷项(减:借项)                                                                                             
  存货的减少(减:增加)                                     6,136,021.64                  2,424,064.17                
  经营性应收项目的减少(减:增加)                             -41,855,535.74                -32,259,366.35              
  经营性应付项目的增加(减:减少)                             -12,959,112.49                -10,168,871.39              
  其他                                                                                                                 
  经营活动产生的现金流量净额                                 39,137,303.89                 39,264,485.28               
  2.不涉及现金收支的投资和筹资活动:                                                                                  
  债务转为资本                                                                                                         
  一年内到期的可转换公司债券                                                                                           
  融资租入固定资产                                                                                                     
  3、现金及现金等价物净增加情况:                                                                                      
  现金的期末余额                                             131,417,370.94                97,159,405.08               
  减:现金的期初余额                                         157,574,849.75                121,757,840.65              
  加:现金等价物的期末余额                                                                                             
  减:现金等价物的期初余额                                                                                             
  现金及现金等价物净增加额                                   -26,157,478.81                -24,598,435.57              
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  公司法定代表人:肖伟       主管会计工作负责人: 戴翔翎          会计机构负责人: 陈友龙